KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

Hirota, 1998, Gain-of-function mutations of c-kit in human gastrointestinal stromal tumours, Science, 279, 577, 10.1126/science.279.5350.577

Lasota, 1999, Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumours and do not occur in leiomyomas or leiomyosarcomas, Am J Pathol, 154, 53, 10.1016/S0002-9440(10)65250-9

Rubin, 2001, KIT activation is a ubiquitous feature of gastrointestinal stromal tumours, Cancer Res, 61, 8118

Lux, 2000, KIT extracellular and kinase domain mutations in gastrointestinal stromal tumours, Am J Pathol, 156, 791, 10.1016/S0002-9440(10)64946-2

Druker, 1996, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells, Nat Med, 2, 561, 10.1038/nm0596-561

van Oosterom, 2001, Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study, Lancet, 358, 1421, 10.1016/S0140-6736(01)06535-7

Demetri, 2002, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours, N Engl J Med, 347, 472, 10.1056/NEJMoa020461

Verweij, 2004, Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial, Lancet, 364, 1127, 10.1016/S0140-6736(04)17098-0

Zalcberg, 2005, Outcome of patients with advanced gastro-intestinal stromal tumours (GIST) crossing over to a daily imatinib dose of 800mg after progression on 400mg: an international intergroup study of the EORTC, ISG and AGITG, Eur J Cancer, 41, 1751, 10.1016/j.ejca.2005.04.034

Van Glabbeke, 2005, Initial and late resistance to imatinib (IM) in advanced gastro-intestinal stromal tumours (GIST) are predicted by different prognostic factors: an EORTC-ISG-AGITG study, J Clin Oncol, 23, 5795, 10.1200/JCO.2005.11.601

Debiec-Rychter, 2005, Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumours and activity of the PKC412 inhibitor against imatinib-resistant mutants, Gastroenterology, 28, 270, 10.1053/j.gastro.2004.11.020

Heinrich, 2003, Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour, J Clin Oncol, 21, 4342, 10.1200/JCO.2003.04.190

Debiec-Rychter, 2004, Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group, Eur J Cancer, 40, 689, 10.1016/j.ejca.2003.11.025

Mick, 2000, Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint, Control Clin Trials, 21, 343, 10.1016/S0197-2456(00)00058-1

Duensing, 2004, Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumours (GISTs), Oncogene, 23, 3999, 10.1038/sj.onc.1207525

Corless, 2004, Biology of gastrointestinal stromal tumours, J Clin Oncol, 22, 3813, 10.1200/JCO.2004.05.140

Lev, 1991, A specific combination of substrates is involved in signal transduction by the kit-encoded receptor, EMBO J, 10, 647, 10.1002/j.1460-2075.1991.tb07993.x

Lennartsson, 1999, Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction, Oncogene, 18, 5546, 10.1038/sj.onc.1202929